Nab-paclitaxel
About
Therapy type: Chemotherapy
Therapy strategy: Taxane-based chemotherapy
Mappings
NCI Thesaurus: Nab-paclitaxel (ncit:C2688)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Nab-paclitaxel, Pembrolizumab | |
| Sensitivity (+) | Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab, Carboplatin, Nab-paclitaxel | |
| Sensitivity (+) | Wild type ALK | Non-Small Cell Lung Cancer | Atezolizumab, Carboplatin, Nab-paclitaxel | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab, Carboplatin, Nab-paclitaxel | |
| Sensitivity (+) | ER negative, HER2-negative, PD-L1 >= 1%, PR negative | Invasive Breast Carcinoma | Atezolizumab, Nab-paclitaxel | |
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab |